Initiator Pharma A/S (INIT.ST)
SEK 7.0
(-1.41%)
SEK 7.0
(-1.41%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.64 Million | -32.7 Million | -34.09 Million | -8.06 Million | -8.55 Million | -13.58 Million |
| Net Income | -27.7 Million | -44.13 Million | -24.24 Million | -10.53 Million | -9.33 Million | -12.61 Million |
| Depreciation & Amortization | - | - | 11 Thousand | 26 Thousand | 87 Thousand | 88 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 4.55 Million | 8.78 Million | -11.4 Million | 463 Thousand | -1.07 Million | -2.7 Million |
| Other non-cash items | 666.00 | 2.64 Million | 1.54 Million | 1.97 Million | 1.77 Million | 1.64 Million |
| Investing Cash Flow | - | -17 Thousand | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -17 Thousand | - | - | - | - |
| Financing Cash Flow | 2.87 Million | 37.48 Million | 54.93 Million | 14 Million | 1.62 Million | 20.9 Million |
| Debt repayment | -2860.00 | - | -13.29 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 12 Thousand | 37.48 Million | 41.64 Million | 14 Million | 1.62 Million | 20.9 Million |
| Other Financing Activities | 2.85 Million | 37.48 Thousand | 13.29 Million | 14 Thousand | 1000.00 | 20.9 Million |
| Accounts receivables | 2.26 Million | 13.03 Thousand | -15.63 Thousand | 127.00 | -1844.00 | -125 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 4559.00 | 8.77 Million | -11.39 Million | 462.87 Thousand | -1.07 Million | 1000.00 |
| Cash at beginning of period | 39.11 Million | 34.34 Million | 13.5 Million | 7.56 Million | 14.49 Million | 7.16 Million |
| Cash at end of period | 24.33 Million | 39.11 Million | 34.34 Million | 13.5 Million | 7.56 Million | 14.49 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -14.77 Million | 4.76 Million | 20.84 Million | 5.94 Million | -6.92 Million | 7.32 Million |
| Free Cash Flow | -17.64 Million | -32.7 Million | -34.09 Million | -8.06 Million | -8.55 Million | -13.58 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.78 Million | -4.12 Million | -27.7 Million | -3.4 Million | -4.61 Million | -10.42 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 513 Thousand | -2.67 Million | 4.55 Million | 548 Thousand | -2.13 Million | 2.42 Million |
| Other non-cash items | - | - | 666.00 | 313.00 | - | 206 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 1.22 Million | 2.87 Million | 265 Thousand | 2.59 Million | 11 Thousand |
| Debt repayment | - | -15.43 Thousand | -2860.00 | -265.00 | -2595.00 | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -580 Thousand | - | - | - | - |
| Common Stock Issuance | - | 17.24 Million | 12 Thousand | 1000.00 | - | 11 Thousand |
| Other Financing Activities | - | -15.43 Million | 2.85 Million | 264 Thousand | 2.59 Million | 11.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 513.00 | -2679.00 | 4559.00 | 548.00 | -2.13 Million | 2.42 Million |
| Cash at beginning of period | 18.76 Million | 24.33 Million | 39.11 Million | 21.78 Million | 25.93 Million | 33.71 Million |
| Cash at end of period | 14.48 Million | 18.76 Million | 24.33 Million | 24.33 Million | 21.78 Million | 25.93 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -4.27 Million | -5.57 Million | -14.77 Million | 2.55 Million | -4.15 Million | -7.78 Million |
| Free Cash Flow | -4.27 Million | -6.8 Million | -17.64 Million | 2.28 Million | -6.74 Million | -7.79 Million |
CAKE
SPMTF
ALCOF
GAGV
NCEN
007700